Corpus overview


Overview

MeSH Disease

HGNC Genes

Transmission

There are no transmission terms in the subcorpus


Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page




    Possible Cross-Reactivity Between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease MESHD and Death MESHD

    Authors: Robert Root-Bernstein

    id:10.20944/preprints202007.0141.v3 Date: 2020-09-04 Source: Preprints.org

    Various studies indicate that vaccination, especially with pneumococcal vaccines MESHD, protects against symptomatic cases of SARS-CoV-2 infection MESHD and death. This paper explores the possibility that pneumococcal vaccines MESHD in particular, but perhaps other vaccines as well, contain antigens that might be cross-reactive with SARS-CoV-2 antigens. Comparison of the glycosylation structures of SARS-CoV-2 with the polysaccharide structures of pneumococcal MESHD vaccines yielded no obvious similarities. However, while pneumococcal MESHD vaccines are primarily composed of capsular polysaccharides, some are conjugated to CRM197, a modified diphtheria toxin, and all contain about three percent protein contaminants, including the pneumococcal MESHD surface proteins PsaA, PspA HGNC and probably PspC. All of these proteins have very high degrees of similarity, using very stringent criteria, with several SARS-CoV-2 proteins including the spike protein, membrane protein and replicase 1a. CRM197 is also present in Hib and meningitis vaccines MESHD meningitis vaccines HP. Equivalent similarities were found at lower rates, or were completely absent, among the proteins in diphtheria, tetanus MESHD, pertussis, measles, mumps, rubella MESHD, and poliovirus vaccines. Notably, PspA HGNC and PspC are highly antigenic and new pneumococcal MESHD vaccines based on them are currently in human clinical trials so that their effectiveness against SARS-CoV-2 disease MESHD is easily testable.

    Possible Cross-Reactivity Between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease MESHD and Death MESHD

    Authors: Robert Root-Bernstein

    id:10.20944/preprints202007.0141.v2 Date: 2020-08-04 Source: Preprints.org

    Various studies indicate that vaccination, especially with pneumococcal vaccines MESHD, protects against symptomatic cases of SARS-CoV-2 infection MESHD and death. This paper explores the possibility that pneumococcal vaccines MESHD in particular, but perhaps other vaccines as well, contain antigens that might be cross-reactive with SARS-CoV-2 antigens. Comparison of the glycosylation structures of SARS-CoV-2 with the polysaccharide structures of pneumococcal MESHD vaccines yielded no obvious similarities. However, while pneumococcal MESHD vaccines are primarily composed of capsular polysaccharides, some are conjugated to CRM197, a modified diphtheria toxin, and all contain about three percent protein contaminants, including the pneumococcal MESHD surface proteins PsaA, PspA HGNC and probably PspC. All of these proteins have very high degrees of similarity, using very stringent criteria, with several SARS-CoV-2 proteins including the spike protein, membrane protein and replicase 1a. CRM197 is also present in Hib and meningitis HP meningitis MESHD vaccines. Equivalent similarities were found at statistically significantly lower rates, or were completely absent, among the proteins in diphtheria, tetanus MESHD, pertussis, measles, mumps, rubella MESHD, and poliovirus vaccines. Notably, PspA HGNC and PspC are highly antigenic and new pneumococcal MESHD vaccines based on them are currently in human clinical trials so that their effectiveness against SARS-CoV-2 disease MESHD is easily testable.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.